Brief: EMA's CHMP Recommends Extensions Of Indication For Bexsero & Talzenna
BRIEF-EMA's CHMP Recommends Extensions Of Indication For Bexsero & Talzenna Nov 13 (Reuters) - EMA's CHMP:
EMA'S CHMP: RECOMMENDED EXTENDING USE OF GAZYVARO (OBINUTUZUMAB) TO TREAT ADULTS WITH MODERATE-TO-SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
EMA'S CHMP: RECOMMENDS GRANTING MARKETING AUTHORISATION FOR BAXFENDY
EMA'S CHMP: RECOMMENDED EXTENSIONS OF INDICATION FOR BEXSERO, COSENTYX, DOVATO, ENFLONSIA, STEGLATRO, SUNLENCA, TALZENNA, TIVICAY, WELIREG
EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR TALZENNA
EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR STEGLATRO
EMA'S CHMP: ADOPTED DHPC ABOUT POTENTIAL EFFECT OF MOUNJARO (TIRZEPATIDE) ON RELIABILITY OF ORAL CONTRACEPTIVES
EMA'S CHMP: DHPC REMINDS HEALTHCARE PROFESSIONALS THAT CONTRACEPTION IS RECOMMENDED FOR WOMEN WHO CAN BECOME PREGNANT & USING MOUNJARO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca fends off lawsuit over alleged Soliris drug monopoly (updated)
AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
Sofinnova closes €725 million fund to back European biotech expansion
AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
UK Stocks-Factors to watch on November 16 (updated)